BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38033490)

  • 1. Eflornithine for chemoprevention in the high-risk population of colorectal cancer: a systematic review and meta-analysis with trial sequential analysis.
    Yang L; Wang Y; Hu S; Wang X
    Front Oncol; 2023; 13():1281844. PubMed ID: 38033490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
    Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
    Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas.
    Zell JA; Lin BS; Madson N; McLaren CE; Gerner EW; Meyskens FL
    Cancer Causes Control; 2012 Oct; 23(10):1739-44. PubMed ID: 22907422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials.
    Veettil SK; Lim KG; Ching SM; Saokaew S; Phisalprapa P; Chaiyakunapruk N
    BMC Cancer; 2017 Nov; 17(1):763. PubMed ID: 29137605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
    Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
    Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.
    Meyskens FL; McLaren CE; Pelot D; Fujikawa-Brooks S; Carpenter PM; Hawk E; Kelloff G; Lawson MJ; Kidao J; McCracken J; Albers CG; Ahnen DJ; Turgeon DK; Goldschmid S; Lance P; Hagedorn CH; Gillen DL; Gerner EW
    Cancer Prev Res (Phila); 2008 Jun; 1(1):32-8. PubMed ID: 18841250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
    Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
    Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.
    Zell JA; Pelot D; Chen WP; McLaren CE; Gerner EW; Meyskens FL
    Cancer Prev Res (Phila); 2009 Mar; 2(3):209-12. PubMed ID: 19258540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention.
    Rial NS; Meyskens FL; Gerner EW
    Essays Biochem; 2009 Nov; 46():111-24. PubMed ID: 20095973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of chemopreventive agents on the incidence of colorectal adenomas: A systematic review and network meta-analysis.
    Heer E; Ruan Y; Mah B; Nguyen T; Lyons H; Poirier A; Boyne DJ; O'Sullivan DE; Heitman SJ; Hilsden RJ; Forbes N; Brenner DR
    Prev Med; 2022 Sep; 162():107169. PubMed ID: 35878711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.
    Thompson PA; Wertheim BC; Zell JA; Chen WP; McLaren CE; LaFleur BJ; Meyskens FL; Gerner EW
    Gastroenterology; 2010 Sep; 139(3):797-805, 805.e1. PubMed ID: 20538001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supplemental calcium in the chemoprevention of colorectal cancer: a systematic review and meta-analysis.
    Carroll C; Cooper K; Papaioannou D; Hind D; Pilgrim H; Tappenden P
    Clin Ther; 2010 May; 32(5):789-803. PubMed ID: 20685491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas.
    Raj KP; Zell JA; Rock CL; McLaren CE; Zoumas-Morse C; Gerner EW; Meyskens FL
    Br J Cancer; 2013 Feb; 108(3):512-8. PubMed ID: 23340449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DFMO: targeted risk reduction therapy for colorectal neoplasia.
    Laukaitis CM; Gerner EW
    Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):495-506. PubMed ID: 22122766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of calcium on the incidence of recurrent colorectal adenomas: A systematic review with meta-analysis and trial sequential analysis of randomized controlled trials.
    Veettil SK; Ching SM; Lim KG; Saokaew S; Phisalprapa P; Chaiyakunapruk N
    Medicine (Baltimore); 2017 Aug; 96(32):e7661. PubMed ID: 28796047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of chemopreventive agents on the incidence of recurrent colorectal adenomas: a systematic review with network meta-analysis of randomized controlled trials.
    Veettil SK; Teerawattanapong N; Ching SM; Lim KG; Saokaew S; Phisalprapa P; Chaiyakunapruk N
    Onco Targets Ther; 2017; 10():2689-2700. PubMed ID: 28579807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.
    Cole BF; Logan RF; Halabi S; Benamouzig R; Sandler RS; Grainge MJ; Chaussade S; Baron JA
    J Natl Cancer Inst; 2009 Feb; 101(4):256-66. PubMed ID: 19211452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.
    McLaren CE; Fujikawa-Brooks S; Chen WP; Gillen DL; Pelot D; Gerner EW; Meyskens FL
    Cancer Prev Res (Phila); 2008 Dec; 1(7):514-21. PubMed ID: 19139001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.